![Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling](https://www.science.org/cms/10.1126/scisignal.aai8441/asset/236282b7-67c8-485b-87f5-2c5e8c53b95c/assets/graphic/9_ra117_f1.jpeg)
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
![Human brain opioid receptor PET images in coronal (upper row) and axial... | Download Scientific Diagram Human brain opioid receptor PET images in coronal (upper row) and axial... | Download Scientific Diagram](https://www.researchgate.net/publication/337338731/figure/fig1/AS:826866776678406@1574151810192/Human-brain-opioid-receptor-PET-images-in-coronal-upper-row-and-axial-lower-row.png)
Human brain opioid receptor PET images in coronal (upper row) and axial... | Download Scientific Diagram
![Platelet Proteomes, Pathways, and Phenotypes as Informants of Vascular Wellness and Disease | Arteriosclerosis, Thrombosis, and Vascular Biology Platelet Proteomes, Pathways, and Phenotypes as Informants of Vascular Wellness and Disease | Arteriosclerosis, Thrombosis, and Vascular Biology](https://www.ahajournals.org/cms/asset/51337fbb-c35a-4b29-b434-91239ac55eb5/atvbaha.120.314647.fig04.jpg)
Platelet Proteomes, Pathways, and Phenotypes as Informants of Vascular Wellness and Disease | Arteriosclerosis, Thrombosis, and Vascular Biology
![Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA) Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)](https://nida.nih.gov/sites/default/files/styles/content_image_medium/public/images/valenza_zamarripa_promo.jpg?itok=HRbtRBEw)
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
![Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA) Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)](https://nida.nih.gov/sites/default/files/images/valenza_zamarripa_fig_3.gif)
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
Subtlety of the Structure−Affinity and Structure−Efficacy Relationships around a Nonpeptide Oxytocin Receptor Agonist | Journal of Medicinal Chemistry
![Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling](https://www.science.org/cdn-cgi/image/width=400/cms/asset/436c9e1a-b8e0-4b88-8135-4a149c22ac29/signaling.2023.16.issue-774.largecover.jpg)
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
![Opioid system and human emotions - Nummenmaa - 2018 - British Journal of Pharmacology - Wiley Online Library Opioid system and human emotions - Nummenmaa - 2018 - British Journal of Pharmacology - Wiley Online Library](https://bpspubs.onlinelibrary.wiley.com/cms/asset/53970599-d0db-49ac-8df6-253f74e6eed2/bph13812-fig-0001-m.jpg)
Opioid system and human emotions - Nummenmaa - 2018 - British Journal of Pharmacology - Wiley Online Library
![Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling](https://www.science.org/cms/10.1126/scisignal.aai8441/asset/c4b5daf9-bb92-4d81-a968-9dba715fc066/assets/graphic/9_ra117_f3.jpeg)
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence
![Cells | Free Full-Text | Intranasal Peptide Therapeutics: A Promising Avenue for Overcoming the Challenges of Traditional CNS Drug Development Cells | Free Full-Text | Intranasal Peptide Therapeutics: A Promising Avenue for Overcoming the Challenges of Traditional CNS Drug Development](https://pub.mdpi-res.com/cells/cells-11-03629/article_deploy/html/images/cells-11-03629-g001.png?1668770287)
Cells | Free Full-Text | Intranasal Peptide Therapeutics: A Promising Avenue for Overcoming the Challenges of Traditional CNS Drug Development
![Subtlety of the Structure−Affinity and Structure−Efficacy Relationships around a Nonpeptide Oxytocin Receptor Agonist | Journal of Medicinal Chemistry Subtlety of the Structure−Affinity and Structure−Efficacy Relationships around a Nonpeptide Oxytocin Receptor Agonist | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/jm901084f/asset/images/medium/jm-2009-01084f_0011.gif)
Subtlety of the Structure−Affinity and Structure−Efficacy Relationships around a Nonpeptide Oxytocin Receptor Agonist | Journal of Medicinal Chemistry
![The mixed kappa and delta opioid receptor agonist, MP1104, attenuates chemotherapy-induced neuropathic pain - ScienceDirect The mixed kappa and delta opioid receptor agonist, MP1104, attenuates chemotherapy-induced neuropathic pain - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S002839082030513X-fx1.jpg)